Skip to Content

Notice

Manufacturer of Controlled Substances Registration: S & B Pharma, Inc.

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

ACTION:

Notice of registration.

SUMMARY:

S & B Pharma, Inc. applied to be registered as a manufacturer of certain basic classes of controlled substances. The DEA grants S & B Pharma, Inc. registration as a manufacturer of those controlled substances.

End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

By notice dated July 1, 2014, and published in the Federal Register on July 8, 2014, 79 FR 38564, S & B Pharma, Inc., DBA Norac Pharma, 405 South Motor Avenue, Azusa, California 91702-3232 applied to be registered as a manufacturer of certain basic classes of controlled substances. No comments or objections were submitted to this notice.

The Drug Enforcement Administration (DEA) has considered the factors in 21 U.S.C. 823(a) and determined that the registration of S & B Pharma, Inc. to manufacture the basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated the company's maintenance of effective controls against diversion by inspecting and testing the company's physical security systems, verifying the company's compliance with state and local laws, and reviewing the company's background and history.

Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above-named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed:

Controlled SubstanceSchedule
Gamma Hydroxybutyric Acid (2010)I
Tetrahydrocannabinols (7370)I
Methamphetamine (1105)II
Pentobarbital (2270)II
Nabilone (7379)II
4-Anilino-N-phenethyl-4-piperidine (ANPP) (8333)II
Tapentadol (9780)II
Fentanyl (9801)II

The company plans to manufacture the listed controlled substances in bulk for use in product development and for commercial sales to its customers.

Start Signature

Dated: January 9, 2015.

Joseph T. Rannazzisi,

Deputy Assistant Administrator.

End Signature End Supplemental Information

[FR Doc. 2015-01287 Filed 1-23-15; 8:45 am]

BILLING CODE P